Retraction note to:RNA-binding protein CPSF6 regulates IBSP to affect pyroptosis in gastric cancer

The authors have decided to retract the article published on World J Gastrointest Oncol(2023)for further consideration due to data errors and some misunderstandings in communication.

Liver cancer: challenge and prospect

According to GLOBOCAN 2012,liver cancer is the sixth most common cancer in the world.There were 782,000 new cases diagnosed in 2012,with 50%in China alone.Liver cancer is the second most common cause of cancer death worldwide and its prognosis is very poor.The World Health Organization(WHO)declared 745,517 deaths caused by liver cancer in 2012,with more than half from China^1.

Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma：a systematic review and meta-analysis

Objective: To compare the effects and safety of conventional transarterial chemoembolization(c TACE) and yttrium-90 transarterial radioembolization [TARE(90 Y)] for hepatocellular carcinoma(HCC)Methods: Nine high-quality observational studies, one low bias-risk randomized controlled trial(RCT), and one moderate biasrisk RCT included 1,652 patients [c TACE, 1,124; TARE(90 Y), 528], from whom data were extracted for this systematic review and meta-analysis.Results: The extracted study outcomes included 1-year and 2-year overall survival(OS) rates, objective responses(ORs), and serious adverse events(AEs). 1-year OS rates: OR = 0.939, 95 % CI: 0.705-1.251, P = 0.66. 2-year OS rates: overall pooled OR =0.641, 95% CI: 0.382-1.075, P = 0.092; observational study subgroup OR = 0.575, 95% CI: 0.336-0.984, P = 0.043; RCT subgroup OR* = 0.641, 95% CI: 0.382-1.075, P = 0.346. OR: overall pooled OR = 0.781, 95% CI: 0.454-1.343, P = 0.371; m RECIST subgroup OR = 0.584, 95 % CI: 0.349-0.976, P = 0.040; WHO subgroup OR = 1.065; 95% CI: 0.500-2.268, P = 0.870. Serious AEs: overall pooled RR = 1.477, 95% CI: 0.864-2.526, P = 0.154; RCT subgroup RR = 0.680, 95% CI: 0.325-1.423, P = 0.306; observational study subgroup RR = 1.925; 95 % CI: 0.978-3.788, P = 0.058.Conclusions: TARE(90 Y) increased 2-year OS rates in the observational subgroup and resulted in better OR rates, according to m RECIST criteria, in comparison with c TACE. Furthermore, a lower risk of AEs was observed for TARE(90 Y) than for c TACE.

Surgical treatment of intrahepatic cholangiocarcinoma: a retrospective study of 104 cases

Objective: To explore the clinicopathological features, surgical treatment techniques, and prognostic risk factors of intrahepatic cholangiocarcinoma(ICC).Methods: A total of 104 ICC cases were collected from January 2008 to December 2013 at Tianjin Medical University Cancer Institute and Hospital and divided into the hepatic hilum lymphadenectomy(HLL, 21 cases), extended hepatic hilum lymphadenectomy(EHLL, 12 cases), and non-lymphadenectomy(NL, 71 cases) groups. The clinical data of the patients were retrospectively analyzed, and the prognostic differences were compared among different groups.Results: The 1-, 2-, and 3-year overall survival(OS) rates of all cases were 72.1%, 56.1%, and 43.7%, respectively. The median survival duration was 34 months. The 1-, 2-, and 3-year OS rates of the HLL group(42.9%, 28.6%, and 28.6%, respectively) were significantly lower than those of the NL group(78.9%, 62.5%, and 47.8%, respectively). Meanwhile, the 1-, 2-, and 3-year OS rates of the EHLL group(75.0%, 56.1%, and 33.3%, respectively) were not significantly different from those of the other two groups.Univariate analysis showed that age, gender, American Joint Committee on Cancer(AJCC) stage, differentiation, ferritin(Fer),carbohydrate antigen19-9(CA19-9) and carcinoembryonicantigen(CEA) levels, lymph node metastasis(LNM), and lymph node dissection(LND) were prognostic factors for the long-term survival of ICC. Meanwhile, multivariate analysis revealed that age,AJCC stage, differentiation, Fer levels, and LNM were independent risk factors for survival.Conclusions: ICC patients will not benefit from lymphadenectomy in the absence of LNM. However, systematic lymphadenectomy may improve ICC outcomes if the location of lymphatic metastasis is known. Age, AJCC stage, differentiation,Fer level, and LNM are independent risk factors for survival in ICC.

The Role of 1q21 Gain on the Prognosis of Multiple Myeloma

Multiple myeloma(MM)is a clonal expansion of malignant plasma cells,and comprises approximately 10%of hematologic malignancies.Although various therapeutic agents and strategies,such as immunomodulatory agents,proteasome inhibitors,monoclonal antibodies and hematopoietic stem cell transplantation(HSCT)have been evaluated,MM remains largely incurable.It is therefore important to further explore the risk factors for disease progression,and to design trials aimed at improving the patient outcomes.Previous studies have considered the presence of a gain in 1q21 as a risk factor for a poorer overall survival.Gain of 1q21 is one of the most common chromosomal aberrations in MM,being detected by fluorescence in situ hybridization in 36%to 47%of newly-diagnosed patients,as well as 52%and 62%patients with relapsed MM.Although a series of reports identified 1q21 gain in MM as a significant and independent poor prognostic factor,other studies failed to demonstrate any prognostic value.Thus,the prognostic value of 1q21 gain in MM remains controversial.We reviewed the current knowledge about 1q21 gain and its value for the clinical management of MM.

LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity to chemotherapy in breast cancer

Lysine-specific demethylase 1 （LSD1） was the first histone demethylase identified as catalysing the removal of mono- and di-methylation marks on histone H3-K4. Despite the potential broad action of LSD1 in transcription regulation, recent studies indicate that LSD1 may coordinate with multiple epigenetic regulatory complexes including CoREST/HDAC complex, NuRD complex, SIRT1, and PRC2, implying complicated mechanistic actions of this seemingly simple enzyme. Here, we report that LSD1 is also an integral component of the SIN3A/HDAC complex. Transcriptional target analysis using ChIP-on-chip technology revealed that the LSD1/SIN3A/HDAC complex targets several cellular signalling pathways that are critically involved in cell proliferation, survival, metastasis, and apoptosis, especially the p53 signalling pathway. We have demonstrated that LSD1 coordinates with the SIN3A/HDAC complex in inhibiting a series of genes such as CASP7, TGFB2, CDKN1A（p21）, HIF1A, TERT, and MDM2, some of which are oncogenic. Our experiments also found that LSD1 and SIN3A are required for optimal survival and growth of breast cancer cells while also essential for the maintenance of epithelial homoeostasis and chemosensitivity. Our data indicate that LSD1 is a functional alternative subunit of the SIN3A/HDAC complex, providing a molecular basis for the interplay of histone demethylation and deacetylation in chromatin remodelling, and suggest that the LSD1/SIN3A/HDAC complex could be a target for breast cancer therapeutic strategies.

Effects of Compound Zhebei Granule(复方浙贝颗粒) Combined with Doxorubicin on Expression of Specific Surface Antigens in Mice with Transplanted KG-1a Cells

Objective：To investigate the effects of Compound Zhebei Granule（复方浙贝颗粒,CZG）combined with doxorubicin hydrochloride（adriamycin,ADM）on specific surface antigens in mice with KG-1a transplanted cells.Methods：A subcutaneous tumor xenograft model was established by injection of the acute myeloid leukemia cell line KG-1a into the axillary flanks of BALB/c-nude mice.Twenty-four tumor bearing mice were divided into 4groups according to a random number table,including normal saline control group,ADM group,high-dose CZG group,and mid-dose CZG group,with 6 mice in each group.Drug administration occurred on the 14th day after cell inoculation,and normal saline control group mice were gavaged with normal saline at 0.2 m L/10 g every other day.ADM group mice were intraperitoneally injected with ADM 1 mg/kg[conversion of adults,40 mg/（m^2·d）]every other day.High-and mid-dose CZG groups mice were gavaged with CZG at the dose of 8 and 4 g/kg respectively every other day and intraperitoneally injected with ADM（1 mg/kg）every other day.The administration period lasted for10 days.The tumor xenografts were made into mononuclear cell suspensions after dissection,and the expressions of specific surface antigens,including CD34~＋CD38^-,CD34~＋CD38^-CD123~＋,CD34~＋CD38^-CD96~＋and CD34~＋CD38^-CD33~＋,in KG-1a cell line tumor xenografts were detected by flow cytometry.Results：Compared with the control and ADM groups,expression of CD34~＋CD38^-in the two CZG groups was significantly lower（P〈0.05）.Compared with the control group,expression of CD34~＋CD38^-CD123~＋in the two CZG groups decreased（P〈0.05）.The high-dose CZG group showed more obvious outcomes compared with the ADM group（P〈0.05）.Compared with the control and ADM groups,the expression of CD34~＋CD38^-CD96~＋and CD34~＋CD38^-CD33~＋in the two CZG groups decreased（P〈0.05）.Conclusions：CZG combined with doxorubicin could reduce the expression of CD34~＋CD38^-,CD34~＋CD38^-CD123~＋,CD34~＋CD38^-CD96~＋and CD34~＋CD38^-CD33~＋in KG-1a cell line tumor xenografts,which shows that CZG could target leukemia stem cells and play a role in chemosensitization.